Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2026-02-27 @ 10:37 AM
Study NCT ID:
NCT02008006
Status:
TERMINATED
Last Update Posted:
2019-01-08
First Post:
2013-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
Sponsor:
Centre Leon Berard
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Follicular Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Follicular Lymphoma | View |
| None | Chemosensitive relapse | View |
| None | High Dose Chemotherapy | View |
| None | Bendamustine | View |
| None | BeEAM | View |
| None | Autologous Stem Cell Transplantation | View |
| None | Safety | View |
| None | Event Free Survival | View |
| None | Overall Response Rate | View |
| None | Progression Free Survival | View |
| None | Overall Survival | View |
| None | Phase II | View |
| None | World Health Organization (WHO) 1 grade | View |
| None | WHO 2 grade | View |
| None | WHO 3a grade | View |